MedicaidPrior AuthMedium impact
Changes to Clinical Review Criteria pdf
Connecticut Medicaid (HUSKY Health)·CT · Oncology, Hematology, Vascular Surgery +4 more·Provider Bulletin
Effective date
May 1, 2021
We identified it
Jun 20, 2026
Summary
Connecticut Medicaid (HUSKY Health) is implementing new prior authorization policies for two new treatments (Breyanzi and Cyanoacrylate Adhesive) and updating clinical review criteria for nine existing specialized treatments including CAR-T cell therapies, gene therapies, and other advanced procedures effective May 1, 2021.
Action Required
By May 1, 2021: Billing team must obtain prior authorization for Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma and Cyanoacrylate Adhesive for varicose veins using forms from the HUSKY Health website. Update prior authorization tracking for updated policies covering Kymriah, Yescarta, Autologous Chondrocyte Implantation, Botulinum Toxin for chronic migraine, Rehabilitation Services, Treatment of Fecal Incontinence, Tecartus, and Gene-based Therapy for Duchenne Muscular Dystrophy. Contact CHNCT at 1-800-440-5071 for prior authorization questions.